Sonova Holding AG Unsponsored ADR (SONVY)
OTHER OTC:SONVY
Top Page
Sonova Holding AG
(OTC:SONVY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$48.00
▼(-9.28% Downside)
Action:DowngradedDate:11/17/25
Sonova Holding AG's overall stock score reflects strong financial performance and a positive earnings outlook, tempered by bearish technical indicators and a relatively high valuation. The company's robust growth in key segments and successful product launches are significant strengths, while market volatility and currency impacts pose challenges.
Positive Factors
Market share gains & product leadership
Sonova's HI and Audiological Care growing ~7% in local currencies at roughly double market growth shows durable share gains tied to product leadership. New platform rollouts (Phonak Infinio/Sphere, Virto R) and regional organization changes support sustained sales momentum and competitiveness over coming quarters.
Negative Factors
Weakness in Consumer Hearing & Cochlear Implants
Structural demand softness in Consumer Hearing and procurement-driven volatility in Cochlear Implants (notably China volume-based purchasing) create enduring headwinds. These dynamics can reduce growth and installed-base upgrade cycles in key segments, weakening revenue diversification over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Market share gains & product leadership
Sonova's HI and Audiological Care growing ~7% in local currencies at roughly double market growth shows durable share gains tied to product leadership. New platform rollouts (Phonak Infinio/Sphere, Virto R) and regional organization changes support sustained sales momentum and competitiveness over coming quarters.
Read all positive factors
Sonova Holding AG (SONVY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.18B
Dividend Yield2.08%
Average Volume (3M)3.58K
Price to Earnings (P/E)17.5
Beta (1Y)0.78
Revenue Growth7.71%
EPS Growth-5.36%
CountryUS
Employees18,335
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.90
Shares Outstanding298,134,030
10 Day Avg. Volume2,397
30 Day Avg. Volume3,581
Financial Highlights & Ratios
PEG Ratio-2.90
Price to Book (P/B)5.77
Price to Sales (P/S)3.98
P/FCF Ratio23.42
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit4.50
Enterprise Value/Ebitda14.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.68
Revenue Forecast (FY)$4.88B
Sonova Holding AG Business Overview & Revenue Model
Company Description
Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication prod...
How the Company Makes Money
Sonova makes money primarily by selling hearing-care products and associated services through a mix of wholesale and direct-to-consumer channels. A major revenue stream comes from hearing aids (devices sold under its brands) and related ecosystem ...
Sonova Holding AG Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Neutral
The earnings call presented a strong performance in the larger business segments with significant market share gains, supported by successful product launches and innovation. However, challenges in smaller segments, currency headwinds, and a decline in gross margins were notable concerns. The outlook remains positive with growth expectations, but market volatility and currency impacts pose challenges.Positive Updates
Strong Sales Growth in Hearing Instruments and Audiological Care
Combined sales growth of 7% in local currencies for Hearing Instruments and Audiological Care, approximately twice the estimated market growth, indicating significant market share gains.
Negative Updates
Challenges in Consumer Hearing and Cochlear Implants
Consumer Hearing business faced weak markets and lack of significant product launches, while Cochlear Implants were affected by volume-based procurement issues in China and lower upgrade sales.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Sales Growth in Hearing Instruments and Audiological Care
Combined sales growth of 7% in local currencies for Hearing Instruments and Audiological Care, approximately twice the estimated market growth, indicating significant market share gains.
Read all positive updates
Company Guidance
In the recent Sonova Half Year Results 2025-2026 Conference Call, the company reported robust performance, with a notable 7% sales growth in local currencies for its Hearing Instruments (HI) and Audiological Care (AC) businesses, a figure approximately double the estimated market growth. This success was largely attributed to the Phonak Infinio and Infinio Sphere platforms, launched in August 2024, and strategic investments in lead generation. Despite headwinds in the Consumer Hearing and Cochlear Implants segments, Sonova achieved a total sales increase of 4.9% in local currencies, reaching CHF 1.8 billion. The company maintained its full-year outlook, targeting 5% to 9% sales growth and 14% to 18% growth in normalized EBITA at constant exchange rates. Additionally, Sonova highlighted the introduction of new products, including the Virto R and Infinio Ultra, and announced an organizational shift to a four-region model to enhance customer proximity.Sonova Holding AG Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.81B | 3.87B | 3.63B | 3.74B | 3.36B | 2.60B |
| Gross Profit | 2.70B | 2.78B | 2.62B | 2.59B | 2.42B | 1.84B |
| EBITDA | 839.02M | 927.00M | 921.70M | 978.70M | 960.90M | 755.30M |
| Net Income | 516.46M | 540.50M | 601.00M | 647.50M | 649.00M | 581.00M |
Balance Sheet | ||||||
| Total Assets | 5.51B | 5.92B | 5.79B | 5.55B | 5.59B | 5.93B |
| Cash, Cash Equivalents and Short-Term Investments | 511.00M | 687.10M | 513.80M | 414.80M | 612.00M | 1.77B |
| Total Debt | 227.70M | 1.76B | 1.79B | 1.81B | 1.48B | 1.83B |
| Total Liabilities | 3.06B | 3.24B | 3.30B | 3.32B | 3.16B | 3.15B |
| Stockholders Equity | 2.43B | 2.66B | 2.47B | 2.21B | 2.41B | 2.75B |
Cash Flow | ||||||
| Free Cash Flow | 756.68M | 656.10M | 624.70M | 609.10M | 815.90M | 665.50M |
| Operating Cash Flow | 811.50M | 793.70M | 753.30M | 763.40M | 922.50M | 754.70M |
| Investing Cash Flow | -255.30M | -212.70M | -234.00M | -429.50M | -707.00M | -123.60M |
| Financing Cash Flow | -306.90M | -401.80M | -415.30M | -523.50M | -1.37B | 687.60M |
Sonova Holding AG Technical Analysis
Negative
52.91
Price Trends
49.67
Negative
50.78
Negative
53.91
Negative
Market Momentum
-1.59
Negative
35.96
Neutral
75.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Negative. The current price of 52.91 is above the 20-day moving average (MA) of 45.88, above the 50-day MA of 49.67, and below the 200-day MA of 53.91, indicating a bearish trend. The MACD of -1.59 indicates Negative momentum. The RSI at 35.96 is Neutral, neither overbought nor oversold. The STOCH value of 75.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SONVY.
Sonova Holding AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $14.02B | 22.70 | 11.79% | 2.28% | 5.78% | 61.52% | |
69 Neutral | $22.07B | 32.31 | 10.21% | 0.94% | 5.15% | 60.30% | |
68 Neutral | $13.18B | 17.48 | 20.45% | 2.08% | 7.71% | -5.36% | |
68 Neutral | $14.33B | 80.92 | 17.36% | ― | 27.12% | -41.72% | |
65 Neutral | $18.20B | 31.78 | 5.60% | 1.05% | 5.47% | -23.03% | |
64 Neutral | $26.53B | 24.78 | 8.21% | 3.30% | -0.76% | -55.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SONVY
Sonova Holding AG
45.98
-7.72
-14.37%
PODD
Insulet
203.51
-61.21
-23.12%
PHG
Koninklijke Philips
28.05
5.00
21.67%
SNN
Smith & Nephew Snats
33.03
7.75
30.68%
STE
Steris
225.03
4.30
1.95%
ZBH
Zimmer Biomet Holdings
93.01
-9.36
-9.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.